Raymond Urbanski, M.D., Ph.D.
Chief Executive Officer and Chairman
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab. In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
Kathleen Clarence-Smith, M.D., Ph.D.
Vice Chairwoman and President of Neurology Division
Dr. Clarence-Smith founded GTP in 2015. Prior to founding GTP, she co-founded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company's Board from 2008 to 2014. Chase Pharmaceuticals was acquired by Allergan, PLC (AGN) in 2016 for $125 million together with potential addition payments of $875 million based upon regulatory and commercial milestones. Dr. Clarence-Smith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is co-founder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.
Chief Financial Officer and Director
Steven Weldon join GT Biopharma, Inc. as member of the Board of Directors in September 2014 and as our President and Chief Financial Officer in November 2014. Previously, Mr. Weldon was the Chief Financial Officer and a member of the board of directors of GB Sciences, Inc. from September 2005 to November 2014. Mr. Weldon also served as chief executive officer of Growblox Sciences from December 29, 2009, through May 2, 2011, and from April 18, 2012, through March 13, 2014. For several years, he taught accounting and tax courses to undergraduate students at Florida Southern College. He received his Bachelor of Science degree and his Master's in Business Administration from Florida Southern College. Mr. Weldon is a Certified Public Accountant licensed to practice in the State of Florida.
John N Bonfiglio, Ph.D., MBA
Dr. Bonfiglio was a consultant to TapImmune Corporation (NASDAQ:TPIV) from February 2015 to July 2016, and later served as TapImmune Corporation’s President and Chief Operating Officer from July 2016 to April 2017. He was the President and Chief Executive Officer of Oragenics (NYSEAMERICAN:OGEN) from May 2011 to November 2014. He brings extensive business management and strategic growth experience, with a focus on the biopharmaceutical drug industry. Dr. Bonfiglio previously served on the boards of directors of TapImmune Corporation and Microlin Therapeutics. Dr. Bonfiglio received his Ph.D. from the University of California at San Diego and his M.B.A. from Pepperdine University.
Anthony J. Cataldo
Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company's profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.
Geoffrey B. Davis
Mr. Davis has extensive experience representing biotechnology, biomedical, medical device and pharmaceutical companies. During his more than 25 years as a partner at Ropes & Gray, Geoff played a significant role in establishing the firm's internationally-recognized Life Sciences group. His work includes numerous corporate partnering and licensing transactions for major pharmaceutical and medical device companies, as well as for public and private biotechnology companies and major medical centers. He has also worked extensively on public and private financings for biomedical companies of all sizes, ranging from newly organized companies to established industry leaders, on behalf of both companies and their investment bankers.
Mr. Davis received his B.A., cum laude, from Yale University and his J.D., cum laude, from Harvard Law School.
Dr. Peter Kiener
Dr. Peter Kiener has substantial experience in both biologics and immunotherapy, and was most recently the Chief Scientific Officer at Sucampo, which was acquired by Mallinckrodt in February 2018 for approximately $1.2 billion. Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) that was acquired by a consortium led by Fosun Pharmaceutical Group in 2015. Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. During Dr. Kiener's more than 20 years as pharmaceutical executive, he has played a significant role in moving various programs through all aspects of drug development, including discovery, regulatory approval, and post marketing. He has also been substantially involved in the execution of multiple deal types, including private placements, IPO, M&A, strategic partnerships, and licensing deals. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications.
Dr. Kiener also currently serves as the chairman of board of directors of Cue Biopharma and as a member of board of directors of Tetragenetics. Previously, has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation and as a member of the Board of Directors of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc.
Peter received his B.A. (1st Class Honors), from Lancaster University in Lancaster, UK and his Ph.D. from Oxford University, Sir William Dunn School of Pathology.